Compliance with Recommendations for Lipid Management among Patients with Type 2 Diabetes in an Academic Family Practice

References

1. ↵
   Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974; 23: 105–11.

   OpenUrlAbstract/FREE Full Text
2. ↵
   Grover S, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 2000; 102: 722–7.

   OpenUrlAbstract/FREE Full Text
3. ↵
   Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ 1989; 299: 1127–31.
4. Stamler J, Vaccaro O, Neaton J, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44.

   OpenUrlAbstract/FREE Full Text
5. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 160–78.

   OpenUrlAbstract/FREE Full Text
6. ↵
   Betteridge DJ. Diabetic dyslipidaemia: treatment implications. J Intern Med Suppl 1994; 736: 47–52.

   OpenUrlPubMed
7. ↵
   Betteridge DJ. Lipids and atherogenesis in diabetes mellitus. Atherosclerosis 1996; 124: S43–7.
8. ↵
   Dunn FL. Management of hyperlipidemia in diabetes mellitus. Endocrinol Metab Clin North Am 1992; 21: 395–414.

   OpenUrlPubMed
9. ↵
   Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614–20.

   OpenUrlAbstract/FREE Full Text
10. ↵
    Steiner G. Lipid intervention trials in diabetes. Diabetes Care 2000; 23: B49–53.
11. ↵
    American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26 Suppl 1: S33–50.
12. ↵
    Charlson M, Pompei P, Ales K, Mackenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373–83.

    OpenUrlCrossRefPubMedWeb of Science
13. Charlson M, Szatrowski T, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–51.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    West DW, Satariano WA, Ragland DR, Hiatt RA. Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol 1996; 6: 413–9.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459–67.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    Andrade SE, Saperia GM, Berger ML, Platt R. Effectiveness of antihyperlipidemic drug management in clinical practice. Clin Ther 1999; 21: 1973–87.

    OpenUrlCrossRefPubMed
17. Allison TG, Squires RW, Johnson BD, Gau GT. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. Mayo Clin Proc 1999; 74: 466–73.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999; 14: 711–7.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    Latts LM. Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans. Am J Med 2001; 110: 17S–23S.
20. ↵
    Vicari RM, Wan GJ, Aura AM, Alexander CM, Markson LE, Teutsch SM. Use of simvastatin treatment in patients with combined hyperlipidemia in clinical practice. For the Simvastatin Combined Hyperlipidemia Registry Group. Arch Fam Med 2000; 9: 898–905.

    OpenUrlPubMed
21. ↵
    Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605–10.

    OpenUrlCrossRefPubMedWeb of Science
22. ↵
    O’Brien T, Nguyen T, Zimmerman B. Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 1998; 73: 969–76.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    Mottur-Pilson C, Snow V, Bartlett K. Physician explanations for failing to comply with “best practices.” Eff Clin Pract 2001; 4: 201–13.

    OpenUrl
24. ↵
    Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 1458–65.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000; 20: 1508–16.

    OpenUrlCrossRefPubMedWeb of Science
26. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000; 20: 1375–83.

    OpenUrlCrossRefPubMedWeb of Science
27. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. J Am Pharm Assoc (Wash) 2000; 40: 157–65.
28. ↵
    Bogden PE, Koontz LM, Williamson P, Abbott RD. The physician and pharmacist team. An effective approach to cholesterol reduction. J Gen Intern Med 1997; 12: 158–64.

    OpenUrlCrossRefPubMedWeb of Science